READ / RESEARCH · ELECTRICAL VESTIBULAR NERVE STIMULATION
<aside>
This paper tests a portable headset that sends a small electrical current through pads behind the ears, aiming to stimulate the vestibular system involved in balance. Participants used it at home for 30 minutes daily over four weeks. The active device did not clearly outperform the sham device across the full analysed group. A benefit appeared in the subgroup with moderate-to-severe anxiety.
</aside>
My sticky notes identify two useful starting points: electrical vestibular nerve stimulation (VeNS) delivers a small current through the skin, and the Modius MA1500 is a portable, battery-operated device.
This interests me as another example of a wearable intended to influence bodily processes without requiring the person to follow a breathing rhythm. For my project, I need to understand both the technology and whether the evidence relates to support during an airport journey.
The headset uses electrode pads placed over the mastoid processes: the bony areas behind the ears. It applies electrical stimulation intended to influence the vestibular system, which helps with balance and spatial orientation.
This is different from the ultrasound paper. The technologies use different forms of stimulation and target different nerve pathways. A similar position around the head does not make their mechanisms or evidence interchangeable.
In this trial, participants adjusted the stimulation until they felt a gentle swaying sensation. They were instructed to use it while seated and before sleeping. The study therefore describes a structured treatment session, rather than a device tested while walking around or navigating a busy environment.
The authors discuss possible connections between vestibular stimulation and emotional regulation, but they did not directly test the neural mechanism. I should describe the mechanism as proposed rather than proven by these results.
The study used a randomised, double-blind, sham-controlled design. Participants received either an active headset or a similar-looking comparison device that delivered brief stimulation before tapering off. This provides a stronger comparison than simply measuring people before and after treatment.
The trial randomised 87 participants; the reported intention-to-treat analysis included 80, with 71 completing the intervention. Although recruitment targeted moderate-to-severe anxiety, some participants’ scores fell between screening and baseline. Those with at least mild symptoms at baseline could continue.
Anxiety was assessed using the GAD-7 questionnaire before and after 28 days. Insomnia and quality of life were also assessed.
Across all 80 analysed participants, anxiety scores improved in both groups. The average reduction was 4.95 points with the active device and 3.90 with sham stimulation. The difference between groups was not statistically significant (p = 0.269).
Within the 53-person subgroup with moderate-to-severe anxiety at baseline, the active group improved more in the reported model accounting for usage (p = 0.045). However, the proportion achieving a clinically meaningful reduction of at least four points did not differ significantly between groups.
There were also no significant between-group benefits for insomnia or the measured quality-of-life components. The paper’s positive title therefore needs to be read alongside these narrower findings.
<aside> 💡
The encouraging finding concerns a subgroup after four weeks. It does not demonstrate immediate calming, or a clear benefit across everyone studied.
</aside>